Renalytix plc
Renalytix plc is a UK-incorporated, AIM-listed (previously also Nasdaq-listed, delisted October 2024) AI-driven in vitro diagnostics company focused on chronic kidney disease (CKD). Its lead product, kidneyintelX.dkd, is an FDA-authorized (Breakthrough Designation, De Novo) blood-based prognostic test combining biomarkers, genetics and EHR data to predict rapid progressive kidney function decline in diabetic kidney disease patients. Revenue is generated from testing services (lab fees for kidneyintelX.dkd tests, mainly US Medicare/insurance reimbursed) and pharmaceutical services (collaborations with pharma/research partners). Operations are run through US subsidiary Renalytix AI, Inc. and Irish subsidiary Renalytix AI Limited.
No price history · 7 reported years, FY2019–FY2025
No daily prices have been collected for this company.
| Line | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY202306/23 | FY202406/24 | FY202506/25 |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Gross profit | |||||||
| Operating profit | |||||||
| Net finance cost | |||||||
| Profit before tax | |||||||
| Tax charge | |||||||
| Profit for the year | |||||||
| EBITDA | |||||||
| Basic EPS | |||||||
| Diluted EPS |
USD millions, negatives in brackets. Per-share lines in cents. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
3 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.